Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; lactose; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - multiple myeloma (mm) revlimid is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) revlimid is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) revlimid is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - lenalidomide, quantity: 10 mg - capsule, hard - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - multiple myeloma (mm) revlimid is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) revlimid is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) revlimid is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - lenalidomide, quantity: 5 mg - capsule, hard - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; lactose; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - multiple myeloma (mm) revlimid is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) revlimid is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) revlimid is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 10mg;   - capsule - 10 mg - active: lenalidomide 10mg   excipient: capsugel yellow 4035 capsule blue-green 6579 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 15mg;   - capsule - 15 mg - active: lenalidomide 15mg   excipient: capsule blue 3628 capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 25mg;   - capsule - 25 mg - active: lenalidomide 25mg   excipient: capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 5mg;   - capsule - 5 mg - active: lenalidomide 5mg   excipient: capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 2.5mg;   - capsule - 2.5 mg - active: lenalidomide 2.5mg   excipient: capsule blue-green 6579 capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 20mg;   - capsule - 20 mg - active: lenalidomide 20mg   excipient: capsule blue 3628 capsule blue-green 6579 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - lenalidomide 7.5mg;   - capsule - 7.5 mg - active: lenalidomide 7.5mg   excipient: capsugel yellow 4035 capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation